BILL SUMMARY 
DE HB 332 establishes the Kratom Consumer Protection Act, requiring labeling disclosures for kratom products and prohibiting adulterated or contaminated products. The bill caps 7-OH content at 2% of total alkaloid composition, bans synthetic kratom compounds, requires clear mitragynine and 7-OH labeling, and enforces age restrictions (21+). Youth-targeted advertising is prohibited. This framework aligns with the Secretary Kennedy-led FDA's July 2025 position: allowing regulated natural kratom while restricting synthetic/concentrated products with abuse potential.

WHY IT MATTERS TO MAHA 
MAHA supports DE HB 332 as a model evidence-based regulatory approach around the known benefits of natural kratom. Unlike prohibition bills, HB 332 follows Secretary Kennedy's -led FDA guidance by targeting synthetic/concentrated 7-OH products while preserving natural kratom access under strict consumer protections. Labeling requirements, potency limits, and age restrictions protect public health while respecting adult medical freedom. The bill demonstrates effective regulation without criminalization—exactly what the FDA endorsed. Transparent product standards and consumer protection better serve public health than blanket bans.